Related Experiment Video
Updated: Jun 8, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Intravitreal bevacizumab during pregnancy.
Ryan M Tarantola1, James C Folk, H Culver Boldt
1Vitreoretinal Service, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa, USA.
Retina (Philadelphia, Pa.)
|October 7, 2010
Summary
Intravitreal bevacizumab therapy for ocular conditions during pregnancy led to improved vision in all patients. Both mothers and infants experienced no adverse events, suggesting a safe treatment option.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Choroidal neovascularization (CNV) poses a risk to vision, especially in pregnant women.
- Limited data exists on the safety and efficacy of intravitreal bevacizumab during pregnancy for ocular conditions.
Observation:
- This study observed four pregnant women with various ocular conditions requiring intravitreal bevacizumab.
- Patients received an average of 2.6 injections during pregnancy, with one receiving additional treatment while breastfeeding.
Findings:
- All four patients experienced significant visual acuity improvement (mean 5.75 lines).
- CNV involuted in all cases without further treatment needs.
- All pregnancies resulted in healthy, full-term infants with normal development.
Implications:
- Intravitreal bevacizumab may be a viable treatment option for pregnant patients with specific ocular conditions.
- Further research with larger cohorts and longer follow-up is needed to confirm safety and efficacy.
- This treatment shows promise for preserving vision without compromising maternal or fetal health.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...